Bowel preparation prior to reconstructive urologic surgery in pediatric myelomeningocele patients.
Farber N, Davis R, Grimsby G, Shinder B, Cannon G, Jacobs M, Ost M, Schneck F, Stephany H, Gargollo P, Dwyer M. Bowel preparation prior to reconstructive urologic surgery in pediatric myelomeningocele patients. Canadian Journal Of Urology 2017, 24: 9038-9042. PMID: 28971794.Peer-Reviewed Original ResearchConceptsMechanical bowel preparationReconstructive urologic surgeryBowel preparationUrological surgeryPostoperative complicationsPerioperative measuresStatistically significant differencePostoperative outcomesPediatric patientsMyelomeningocele patientsSignificant differencePreoperative mechanical bowel preparationPreoperative bowel preparationStandard of careAugmentation cystoplastyComplication rateUrinary diversionNo significant differenceRandomized studyPatient populationOperative timeSurgeryComplicationsPatientsMyelomeningocelePerforming all major surgical procedures robotically will prolong wait times for surgery
Shinder BM, Farber NJ, Weiss RE, Jang TL, Kim IY, Singer EA, Elsamra SE. Performing all major surgical procedures robotically will prolong wait times for surgery. Robotic Surgery Research And Reviews 2017, 4: 87-91. PMID: 28890901, PMCID: PMC5586216, DOI: 10.2147/rsrr.s135713.Peer-Reviewed Original ResearchMajor surgical proceduresFellowship-trained surgeonsUrologic oncology proceduresHealth care systemRadical nephrectomyNumber of prostatectomiesSingle institutionTime patientsPartial nephrectomySurgery timeSurgical proceduresSurgical casesOncology proceduresNumber of casesSurgeryRobotic proceduresSurgical fieldMost hospitalsCare systemSurgeonsNumber of daysRS timeNephrectomyPatientsCalendar yearSurgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach
Shinder B, Rhee K, Farrell D, Farber N, Stein M, Jang T, Singer E. Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Frontiers In Oncology 2017, 7: 107. PMID: 28620578, PMCID: PMC5449498, DOI: 10.3389/fonc.2017.00107.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMetastatic renal cell carcinomaRenal cell carcinomaSystemic therapyCell carcinomaSurgical managementSurgical management of patientsImmune checkpoint inhibitorsNeoadjuvant systemic therapyMetastatic kidney cancerCytokine-based immunotherapyOptimal patient selectionManagement of patientsCheckpoint inhibitorsCytoreductive surgeryMetastatic diseasePrimary tumorAdjuvant therapyProspective trialsTherapeutic armamentariumPatient selectionKidney cancerTherapyCarcinomaSurgeryPatients